FemTech Leader Wisp Brings Personalized Care Closer to Home for Women Across the U.S.
San Francisco-based Wisp, a rising FemTech platform focused on accessible sexual and reproductive health, has announced a major expansion to its services. The company is now offering at-home STI testing kits and launching GLP-1 weight management care—a bold move that aims to make women’s health more personalized, discreet, and tech-enabled.
What’s New?
- At-Home STI Testing: Women can now test for common STIs (including chlamydia, gonorrhea, trichomoniasis) from the privacy of their homes. Wisp’s kits are lab-certified and come with follow-up treatment guidance.
- GLP-1 Weight Care: With the popularity of GLP-1 medications like Ozempic and Wegovy, Wisp is offering a virtual weight care program that includes prescriptions, telehealth support, and behavioral coaching for women battling obesity or metabolic disorders.
“We’re continuing to close the gender gap in healthcare by providing women with easy, stigma-free access to diagnostics and treatments,” said Wisp CEO Ahmad Bani.
Why It Matters:
- Over 20 million STIs are diagnosed annually in the U.S., many of which go undetected due to stigma or lack of access.
- Women are disproportionately underserved in both sexual health and obesity care.
- GLP-1s are emerging as a groundbreaking solution for weight-related chronic diseases—and Wisp is among the first to tailor them specifically for women.
Tech-First, Privacy-Focused
Wisp’s telehealth + logistics model allows women to consult doctors, get prescriptions, and receive diagnostic kits—all without stepping into a clinic. The platform is tapping into the growing demand for at-home care, digital health convenience, and female-centric health tech.
🔗 Source: Forbes – Wisp Expands Women’s Health
